TEVA FDA accepts NDA for ecopipam, targets late Q1 2027
TEVA says the FDA has accepted its NDA for ecopipam and set a targeted action date in late Q1 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.